213 related articles for article (PubMed ID: 33238031)
1. RNA-binding motif protein 39 (RBM39): An emerging cancer target.
Xu Y; Nijhuis A; Keun HC
Br J Pharmacol; 2022 Jun; 179(12):2795-2812. PubMed ID: 33238031
[TBL] [Abstract][Full Text] [Related]
2. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.
Han T; Goralski M; Gaskill N; Capota E; Kim J; Ting TC; Xie Y; Williams NS; Nijhawan D
Science; 2017 Apr; 356(6336):. PubMed ID: 28302793
[TBL] [Abstract][Full Text] [Related]
3. Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15.
Ting TC; Goralski M; Klein K; Wang B; Kim J; Xie Y; Nijhawan D
Cell Rep; 2019 Nov; 29(6):1499-1510.e6. PubMed ID: 31693891
[TBL] [Abstract][Full Text] [Related]
4. Insights on the biological functions and diverse regulation of RNA-binding protein 39 and their implication in human diseases.
Eléouët M; Lu C; Zhou Y; Yang P; Ma J; Xu G
Biochim Biophys Acta Gene Regul Mech; 2023 Mar; 1866(1):194902. PubMed ID: 36535628
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex.
Bussiere DE; Xie L; Srinivas H; Shu W; Burke A; Be C; Zhao J; Godbole A; King D; Karki RG; Hornak V; Xu F; Cobb J; Carte N; Frank AO; Frommlet A; Graff P; Knapp M; Fazal A; Okram B; Jiang S; Michellys PY; Beckwith R; Voshol H; Wiesmann C; Solomon JM; Paulk J
Nat Chem Biol; 2020 Jan; 16(1):15-23. PubMed ID: 31819272
[TBL] [Abstract][Full Text] [Related]
6. Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820.
Du X; Volkov OA; Czerwinski RM; Tan H; Huerta C; Morton ER; Rizzi JP; Wehn PM; Xu R; Nijhawan D; Wallace EM
Structure; 2019 Nov; 27(11):1625-1633.e3. PubMed ID: 31693911
[TBL] [Abstract][Full Text] [Related]
7. Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15.
Faust TB; Yoon H; Nowak RP; Donovan KA; Li Z; Cai Q; Eleuteri NA; Zhang T; Gray NS; Fischer ES
Nat Chem Biol; 2020 Jan; 16(1):7-14. PubMed ID: 31686031
[TBL] [Abstract][Full Text] [Related]
8. Proximity Labeling, Quantitative Proteomics, and Biochemical Studies Revealed the Molecular Mechanism for the Inhibitory Effect of Indisulam on the Proliferation of Gastric Cancer Cells.
Lu J; Jiang H; Li D; Chen T; Wang Y; Pu Z; Xu G
J Proteome Res; 2021 Sep; 20(9):4462-4474. PubMed ID: 34420308
[TBL] [Abstract][Full Text] [Related]
9. Targeting the spliceosome through RBM39 degradation results in exceptional responses in high-risk neuroblastoma models.
Singh S; Quarni W; Goralski M; Wan S; Jin H; Van de Velde LA; Fang J; Wu Q; Abu-Zaid A; Wang T; Singh R; Craft D; Fan Y; Confer T; Johnson M; Akers WJ; Wang R; Murray PJ; Thomas PG; Nijhawan D; Davidoff AM; Yang J
Sci Adv; 2021 Nov; 7(47):eabj5405. PubMed ID: 34788094
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis of RNA-binding and autoregulation by the cancer-associated splicing factor RBM39.
Campagne S; Jutzi D; Malard F; Matoga M; Romane K; Feldmuller M; Colombo M; Ruepp MD; Allain FH
Nat Commun; 2023 Sep; 14(1):5366. PubMed ID: 37666821
[TBL] [Abstract][Full Text] [Related]
11. Towards a druggable epitranscriptome: Compounds that target RNA modifications in cancer.
Berdasco M; Esteller M
Br J Pharmacol; 2022 Jun; 179(12):2868-2889. PubMed ID: 34185879
[TBL] [Abstract][Full Text] [Related]
12. Global regulation of alternative RNA splicing by the SR-rich protein RBM39.
Mai S; Qu X; Li P; Ma Q; Cao C; Liu X
Biochim Biophys Acta; 2016 Aug; 1859(8):1014-24. PubMed ID: 27354116
[TBL] [Abstract][Full Text] [Related]
13. Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma.
Nijhuis A; Sikka A; Yogev O; Herendi L; Balcells C; Ma Y; Poon E; Eckold C; Valbuena GN; Xu Y; Liu Y; da Costa BM; Gruet M; Wickremesinghe C; Benito A; Kramer H; Montoya A; Carling D; Want EJ; Jamin Y; Chesler L; Keun HC
Nat Commun; 2022 Mar; 13(1):1380. PubMed ID: 35296644
[TBL] [Abstract][Full Text] [Related]
14. RBM39: A druggable metabolic sensor linking RNA splicing, transcriptional regulation, and metabolic reprogramming in cancer.
Keun HC; Nijhuis A
Mol Cell; 2023 Dec; 83(23):4202-4204. PubMed ID: 38065060
[TBL] [Abstract][Full Text] [Related]
15. Overlaid Transcriptional and Proteome Analyses Identify Mitotic Kinesins as Important Targets of Arylsulfonamide-Mediated RBM39 Degradation.
Coomar S; Mota P; Penson A; Schwaller J; Abdel-Wahab O; Gillingham D
Mol Cancer Res; 2023 Aug; 21(8):768-778. PubMed ID: 37255411
[TBL] [Abstract][Full Text] [Related]
16. Genetic and compound screens uncover factors modulating cancer cell response to indisulam.
Pogacar Z; Groot K; Jochems F; Dos Santos Dias M; Mulero-Sánchez A; Morris B; Roosen M; Wardak L; De Conti G; Velds A; Lieftink C; Thijssen B; Beijersbergen RL; Bernards R; Leite de Oliveira R
Life Sci Alliance; 2022 Sep; 5(9):. PubMed ID: 35534224
[TBL] [Abstract][Full Text] [Related]
17. Protein 4.1R Exon 16 3' Splice Site Activation Requires Coordination among TIA1, Pcbp1, and RBM39 during Terminal Erythropoiesis.
Huang SC; Zhang HS; Yu B; McMahon E; Nguyen DT; Yu FH; Ou AC; Ou JP; Benz EJ
Mol Cell Biol; 2017 May; 37(9):. PubMed ID: 28193846
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D regulation of energy metabolism in cancer.
Sheeley MP; Andolino C; Kiesel VA; Teegarden D
Br J Pharmacol; 2022 Jun; 179(12):2890-2905. PubMed ID: 33651382
[TBL] [Abstract][Full Text] [Related]
19. The importance of Ras in drug resistance in cancer.
Healy FM; Prior IA; MacEwan DJ
Br J Pharmacol; 2022 Jun; 179(12):2844-2867. PubMed ID: 33634485
[TBL] [Abstract][Full Text] [Related]
20. Systematic pan-cancer analysis identifies RBM39 as an immunological and prognostic biomarker.
Zhang R; Wang W; Zhang N; Chen X; Liu W; Zhang L; Liu N
J Cell Mol Med; 2022 Sep; 26(18):4859-4871. PubMed ID: 35989423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
